First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). Matheron, Sophie; Descamps, Diane; Gallien, Sebastien; Besseghir, Amel; Sellier, Pierre; Blum, Laurent; Mortier, Emmanuel; Charpentier, Charlotte; Tubiana, Roland; Damond, Florence; Peytavin, Gilles; Ponscarme, Diane; Collin, Fideline; Brun-Vezinet, Francoise; Chene, Genevieve; France REcherche Nord&Sud Sida-Hiv Hépatites (ANRS) 159 HIV-2 Trial Study Group. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2018; 67: p.1161-1167. doi:10.1093/cid/ciy245
Article